Xatral® 10mg OD

• Treatment for enlarged prostate

• 3 times a day version sales of $100 million - Europe

• Approved France, Netherlands, Denmark, Switzerland

• Approvals / Marketing anticipated remainder of Europe Q1 / Q2

• In Phase III in USA

• Worldwide potential $400 million

Previous slide

Next slide

Back to first slide

View graphic version